USE OF GENETICALLY ENGINEERED MICE AS MODELS FOR EXPLORING THE ROLE OF OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASES

Julie K. Andersen

Division of Biogerontology, Andrus Gerontology Center, University of Southern California, Los Angeles, CA 90089-0191

Received 3/16/98 Accepted 3/20/98

6. REFERENCES

1. Coyle, J.T. & P. Puttfarcken: Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695 (1993)

2. Tritschler, H.J., L. Packer, & R. Medori: Oxidative stress and mitochondrial dysfunction in neurodegeneration. Biochem Mol Bio Int 34, 169-181 (1994)

3. Olanow, C.W. & G.W. Arendash: Metals and free radicals in neurodegeneration. Curr Opin Neurol 7, 548-558 (1994)

4. Williams, L.R: Oxidative stress, age-related neurodegeneration, and the potential for neurotrophic treatment. Cerebrovasc Brain Metab Rev 7, 55-73 (1996)

5. Bowling, A.C. & M.F. Beal: Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 56, 1151-1171 (1995)

6. Beal, M.F: Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38, 357-366 (1995)

7. Fisher, L.J. & F.H. Gage: Radical directions in Parkinson’s disease. Nature Med 3, 201-202 (1995)

8. Ying, W: A new hypothesis of neurodegenerative diseases: a deleterious network hypothesis. Med Hypotheses 47, 307-313 (1996)

9. Jenner, P: Oxidative stress in Parkinson’s disease and other neurodegenerative disorders. Pathol Biol 44, 57-64 (1996)

10. Beal, M.F: Mitochondria, free radicals, and neurodegeneration. Curr Opin Neurobiol 6, 661-666 (1996)

11. Palmiter, R.D. & R. Brinster: Transgenic mice. Cell 41, 343-345 (1985)

12. Capecchi, M.R: The new mouse genetics: altering the genome by gene targeting. Trends Genet 5, 70-76 (1989a)

13. Capecchi, M.R: Altering the genome by homologous recombination. Science 244, 1288-1292 (1989b)

14. Brown, R.H: Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell 80, 687-692 (1995)

15. Rosen, D.R., T.Siddique, D. Patterson, D.A. Figelwicz, P. Sapp, A. Rentati, D. Donaldson, J. Goto, J.P. O’Regan, H.X. Deng, Z. Rahmani, A. Krizus, D. McKenna-Yasek, A. Cayabyab, S.M. Gston, R. Berger, R.E. Tanzi, J. J. Halperin, B. Hertzfeldt, R. Van de Bergh, W.Y. Hung, T. Bird, G. Deng, D.W. Mulder, C. Smyth, N.G. Laing, E. Soriano, M.A. Pericak-Vance, J. Haines, G.A. Rouleau, J.S. Gusella, H.R. Horvitz, & R.H. Brown Jr: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 357-462 (1993)

16. Anderson, P.A., P. Nilsson, V. Ala-Hurula, M.L. Keranen, I Tarvainen, T Haltia, L. Nilsson, M. Binzer, L. Forsgren, & S.L. Markland: Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in Cu/Zn dismutase. Nat Genet 10, 61-66 (1995)

17. Jones, C.T., P.J. Shaw, G. Chari, & D.J. Brock: Identification of a novel exon 4 SOD1 mutation in a sporadic amyotrophic lateral sclerosis patient. Mol Cell Probes 8, 329-330 (1994a)

18. Jones, C.T., R.J. Swingler, & D.J. Brock: Identification of a novel SOD1 mutation in an apparently sporadic amyolateral sclerosis patient and the detection of Ile113Thr in three others. Hum Mol Genet 3, 649-650 (1994b)

19. Tainer, J.A., E.D. Getzoff, K.M. Beem, J.S. Richardson, & D.C. Richardson: Determination and analysis of the 2A structure of copper and zinc superoxide dismutase. J Mol Biol 160, 181-217 (1982)

20. Gurney, M.E., H. Pu, A.Y. Chiu, M.C. Dal Canto, C.Y. Polchow, D.D. Alexander, J. Caliendo, A. Hentati, Y.W. Kwon, H.X. Deng, W. Chen, P. Zhai, R.L. Sufit, & T. Siddique: Motor neuron degeneration in mice that express a human Cu/Zn superoxide gene mutation. Science 264, 1772-1775 (1994)

21. Ripps, M.E., G.W. Huntley, P.R. Hof, J.H. Morrison, & G.W. Gordon: Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 92, 689-693 (1995)

22. Wong, P.C., C.A. Pardo, D.R. Borchelt, M.K. Lee, N.G. Copeland, N.A. Jenkins, S.S. Sisodia, D.W. Cleveland, & D.L. Price: An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuole degeneration of mitochondria. Neuron 14, 1105-1116 (1995)

23. Tu, P.H., P. Raju, K.A. Robinson, M.E. Gurney, J.Q. Trojanowski, & V.M.Y. Lee: Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 93,3155-3160 (1996)

24. Borchelt, D.R., M.K. Lee, H.S. Slunt, M. Guarnieri, Z.S. Xu, P.C. Wong, R.H. Brown Jr, D.L. Price, S.S. Sisodia, & D.W. Cleveland: Superoxide dismutase 1 with mutations linked to familial lateral sclerosis possesses significant activity. Proc Natl Acad Sci USA 91, 8292-8296 (1994)

25. Reaume, A.B. , J.L. Elliot, E.K. Hoffman, N.W. Kowall, R.J. Ferante, D.F. Siwek, H.M. Wilcox, D.G. Flood, M.F. Beal, R.H. Brown, R.W. Scott, & W.D. Snider: Motor neurons in Cu/Zn superoxide dismutase mice develop normally but exhibit enhanced cell death after neuronal injury. Nat Genet 13, 43-47 (1996)

26. Tu, P.H., M.E. Gurney, J.-P. Julien, V.M.Y. Lee, & J.Q. Trojanowski: Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Lab Invest 76, 441-456 (1997)

27. Yim, M.B., J.H. Kang, H.S. Yim, H.S. Kwak, P.B. Chock, & E.R. Stadtman: A gain of function of an amyotropic lateral sclerosis asssociated Cu,Zn superoxide dismutase mutant: an enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc Natl Acad Sci USA 93, 5709-5714 (1996)

28. Wiedau-Pazos, M., J.J. Goto, S. Rabizadeh, E.B. Gralla, J.A. Roe, M.K. Lee, J.S. Valentine, & D.E. Bredesen: Altered reactivity of superoxide dismutase in familial lateral sclerosis. Science 271, 515-518 (1996)

29. Beckman, J.S., M. Carson, C.D. Smith, & W.H. Koppenol: ALS, SOD, and peroxynitrite. Nature 364, 584 (1993)

30. Bruijn, L.I., M.F. Beal, M.W. Becher, J.B. Schultz, P.C. Wong, & D.L. Price: Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA 94, 7606-7611 (1997)

31. Cote, F., J.F. Collard, & J.P. Julien: Progressive neuronopathology in transgenic mice expressing the human neurofilament gene: a mouse model of amyotrophic lateral sclerosis. Cell 73, 35-46 (1993)

32. Figlewicz, D., A. Krizus, M.G. Martinoli, V. Meininger, M. Dib, G.A. Rouleau, & J.P. Julien: Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Molec Genet 3, 1757-1761 (1994)

33. Collard, J.F., F. Cote, & J.P. Julien: Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 37,: 61-64 (1995)

34. Samdani, A.F., T.M. Dawson, & V.L. Dawson: Nitric oxide synthase in models of focal ischemia. Stroke 28, 1283-1288 (1997)

35. Ho, Y.S., J.L. Magnenat, R.T. Bronson, J. Cao, M. Gargano, M. Sugawara, & C.D. Funk: Mice deficient in cellular glutathione peroxidase develop normally and show no increase sensitivity to hyperoxia. J Biol Chem 272, 16644-16651 (1997)

36. Graybiel, A.M: The basal ganglia and the initiation of movement. Rev Neurol 146, 570-574 (1990)

37. Graybiel, A.M., E.C. Hirsch, & Y. Agid: The nigrostriatal system in Parkinson’s disease. Adv Neurol 53, 17-29 (1990)

38. Hirsch, E.C: Why are catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann Neurol 32, S88-S93 (1992)

39. Langston, J.W. & I. Irwin: MPTP: current concepts and controversies, Clin Neuropharmacol 9, 485-507 (1986)

40. Calne, J.L. & J.W. Langston: Aetiology of Parkinson's disease. Lancet ii, 1457-1459 (1983)

41. Langston, J.W: The etiology of Parkinson’s disease with emphasis on the MPTP story. Neurology 47, S153-160 (1996)

42. Przedborski, S., V. Kostic, V. Jackson-Lewis, A.B. Naini, S. Simonetti, S. Fahn, E. Carlson, C.J. Epstein, & J.L. Cadet. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neuroscience 12, 1658-1667 (1992)

43. Hassan, M. & I. Fridovitch: Intracellular production of superoxide radicals and of hydrogen peroxide by redox active compounds. Arch Biochem Biophys 196, 385-395 (1979)

44. Sanchez-Ramos, J.R., S. Song, A. Facca, A. Basit, & C. J. Epstein: Transgenic murine dopominergic neurons expressing human Cu/Zn superoxide dismutase exhibit increased density in culture, but no resistance to methylphenylpyridium-induced degeneration. J Neurochem 68, 58-67 (1997)

45. Nakao, N., E.M. Frodl, H. Widner, E. Carlson, F.A. Eggerding, C.J. Epstein, & P. Brundin: Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson’s disease. Nature Med, 226-231 (1995)

46. Andersen, J.K. , D.M. Frim, O. Isacson, & X.O. Breakefield: Catecholaminergic cell atrophy in a transgenic mouse aberrently overexpressing MAO-B in neurons. Neurodegeneration 3, 97-109 (1994a)

47. Raichi, N.J. & S.I. Harik: Strain differences in systemic 1-methyl-4-phenyl-1,2,3,6-tetrahdropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier, Life Sci 42, 2359-2363 (1988)

48. Giovanni, A., B.S. Sieber, R.E. Heikkila, & P.K. Sonsalla: Correlation between the neostriatal content of the 1-methyl-4-phenylpyridium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J Pharmacol. Exp Therapeut 257, 691-697 (1991)

49. Grimsby, J., M. Toth, K. Chen, T. Kumazawa, L. Klaidman, J.D. Adams, F. Karoum, J. Gal, & J.C. Shih: Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nature Genetics 17, 1-5 (1997)

50. Andersen, J.K., D.M. Frim, O. Isacson, M.F. Beal, & X.O. Breakefield: Elevation of MAO-B in a transgenic mouse model has no effect on MPTP sensitivity. Brain Res 656, 108-114 (1994b)

51. Cohen, G: Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Adv Neurol 45, 119-125 (1986)

52. Wei, Q., M. Yeung, O.P. Jurma, & J.K. Andersen: Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP. J Neurosci Res 46, 666-673 (1996)

53. DiMonte, D.A., P.A. Chan, & M.S. Sandy: Glutathione in Parkinson’s disease: a link between oxidative stress and mitochondrial damage? Ann Neurol 32, S111-115 (1992)

54. Jenner, P.D., A.H.V. Schapira, & C.D. Marsden: Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disorder. Neurol 42, 2241-2250 (1992)

55. Sian, J., D.T. Dexter, A.J. Lees, S. Daniel, Y. Agid, F. Javoy-Agid, P. Jenner, & C.D. Marsden: Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders. Ann Neurol 36, 348-355 (1994)

56. Andersen, J.K., J.-Q. Mo, L.L. Koek, D.G. Hom, & T.H. McNeill: Effects of buthionine sulfoximide, a synthesis inhibitor of the antioxidant glutathione, on murine nigrostriatal neurons. J Neurochem 67, 2164-2171 (1996)

57. Hardy, J: New insights into the genetics of Alzheimer's disease. Ann Med 28, 255-258 (1996)

58. Selkoe, D: The molecular pathology of Alzheimer’s disease. Neuron 6, 487-498 (1993)

59. Mullan, M. & F. Crawford: Genetic and molecular advances in Alzheimer’s disease. Trends Neurosci 16, 398-403 (1993)

60. Games, D., A. Adams, R. Alessandrini, R. Barbour, P. Berthelette, C. Blackwell, T. Carr, J. Clemens, T. Donaldson, F. Gillespie, T. Guido, S. Hagopian, K. Wood-Johnson, K. Khan, M. Lee, P. Liebowitz, I. Leiberburg, S. Little, E. Masliah, L. McConlogue, M. Montoya-Zavala, L. Mucke, L. Paganini, E. Penniman, M. Power, D. Schenk, P. Seubert, B. Snyder, F. Soriano, H. Tan, J. Vitale, S. Wadsworth, B. Wolozin, & J. Zhao: Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523-527 (1995)

61. Hsaio, K., P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang, & G. Cole: Correlative memory deficits, beta-amyloid elevation, and amyloid plaques in transgenic mice. Science 274, 99-103 (1996)

62. Fraser, S.P., Y.-H. Suh, & M.B.A. Djamgoz: Ionic effects of the Alzheimer’s disease beta-amyloid precursor protein and its metabolic fragments. Trends Neurosci 20, 67-72 (1997)

63. Davis, J.B: Oxidative mechanisms in beta-amyloid cytotoxicity. Neurodegeneration 5, 441-444 (1996)

64. Mark, R.J., E.M. Blanc, & M.P. Mattson: Amyloid beta-peptide and oxidative cellular injury in Alzheimer's disease. Mol Neurobiol 12, 211-224 (1996)

65. Harris, M.E., K. Hensley, D.A. Butterfield, R.A. Leedle, & J.M. Carney: Direct evidence of oxidative injury produced by the Alzheimer’s beta-amyloid protein (1-40) in cultured hippocampal neurons. Exp Neurol 131, 193-202 (1995)

66. Mark, R.J., K. Hensley, D.A. Butterfield, & M.P. Mattson: Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal calcium loss homeostasis and cell death. J Neurosci 15, 6239-6249 (1995)

67. Mark, R.J., M.A. Lovell, W.R. Markesbery, K. Uchida, & M.P. Mattson: A role for 4-hydroxynonenal in disruption of ion homeostasis and neuronal death induced by amyloid beta peptide. J Neurosci 58, 255-264 (1997)

68. Bruce, A.J, B. Malfroy, & M. Baudry: Beta-amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. Proc Natl Acad Sci USA 93, 2312-2316 (1996)

69. Zhang, Z., R.E. Rydel, G.J. Drzewiecki, K. Fuson, S. Wright, M. Wogulis, J.E. Audia, P.C. May, & P.A. Hyslop: Beta amyloid-mediated oxidative and metabolic stress in rat cortical neurons: no direct evidence for a role for hydrogen peroxide generation. J Neurochem 67, 1595-1606 (1996)

70. Gusella, J.F., M.E. MacDonald, C.M. Ambrose, & M.P. Duyao: Molecular genetics of Huntington's disease. Arch Neurol 50, 1157-1163 (1993)

71. Duyao, M.P., A.B. Auerbach, A. Ryan, F. Persichetti, G.T. Barnes, S.M. McNeil, P. Ge, J.P. Vonsattel, J.F. Gusella, A.L. Joyner, & M.E. MacDonald: Inactivation of the mouse Huntington’s disease gene homologue Hdh. Science 269, 407-410 (1995)

72. Nasir, J., S.B. Floresco, J.R. O'Kusky, V.M. Diewert, J.M. Richman, J. Zeisler, A. Borowski, J.D. Marth, A.G. Phillips, & M.R. Hayden: Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 2, 811-23 (1995)

73. Beal, M.F., N.W. Kowall, D.W. Ellison, M.F. Mazurek, K.J. Swartz, & J.B. Martin: Replication of the neurochemical characteristics of Huntington’s disease with quinolic acid. Nature 321, 168-171 (1986)

74. Beal, M.F. , N.W. Kowall, K.J. Swartz, Ferrante R.J, & J.B. Martin: Differential sparing of somastatin-neuropeptide Y and cholinergic neurons following striatal excitotoxic lesions. Synapse 3, 38-47 (1989)

75. Albin, R. & J.T. Greenmyare: Alternative excitotoxic hypotheses. Neurology 42, 733-738 (1992)

76. Beal, M.F: Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative disease? Ann Neurol 31: 119-130 (1992)

77. Ludolph, A.C., M. Seelig, & A. Ludolph: 3-nitropropionic acid decreases cellular energy levels and causes neuronal degeneration in cortical implants. Neurodegeneration 1, 155-161 (1992)

78. Brouillet, E.P., B.G. Jenkins, B.T. Hyman, R.J. Ferrante, N.W. Kowall, R. Srivastava, D. Samantha Roy, B.R. Rosen, & M.F. Beal: Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 60, 356-359 (1993)

79. Beal, M.F., R.J. Ferrante, R. Henshaw, R.T. Matthews, P.H. Chan, N.W. Kowall, C.J. Epstein, & J.B. Schultz: 3-nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase mice. J Neurochem 65, 919-922 (1995)

80. Mangiarini, L., K. Sathasivam, M. Seller, B. Cozens, A. Harper, C. Hetherington, M. Lawton, Y. Trottier, H. Lehrach, S.W. Davies, & G.P. Bates: GP Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506 (1996)

81. Wellington, C.L. & M.R. Hayden: Of molecular interactions, mice and mechanisms: new insights into Huntington's disease. Curr Opin Neurol 10, 291-298 (1997)

82. Peyser, C.E., M. Folstein, G.A. Chase, S. Starkstein, J. Brandt, J.R. Cockrell, F. Bylsma, J.T. Coyle, P.R. McHugh, & S.E. Folstein: Trials of alpha-tocopherol in Huntington’s disease. Am J Psychiatry 152, 1771-1775 (1995)